May 17, 2018 / 12:58 PM / 3 months ago

BRIEF-MabVax Therapeutics Receives U.S. Patent For Certain Fully Human Antibodies

May 17 (Reuters) - MabVax Therapeutics Holdings Inc :

* MABVAX THERAPEUTICS RECEIVES U.S. PATENT FOR FULLY HUMAN ANTIBODIES TARGETING THE ANTIGEN GD2 EXPRESSED ON SARCOMA, MELANOMA, AND NEUROBLASTOMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below